Atezolizumab plus bevacizumab vs sorafenib in locally advanced or metastatic hepatocellular carcinoma: The randomised phase III study IMbrave150

被引：0
|
作者：
Ducreux, M. P. [1 ]
Cheng, A-L. [2 ]
Qin, S. [3 ]
Zhu, A. X. [4 ]
Ikeda, M. [5 ]
Kim, T-Y. [6 ]
Xu, D-Z. [7 ]
Verret, W. [8 ]
Liu, J. [7 ]
Finn, R. S. [9 ]
Galle, P. R. [10 ]
机构：
[1] Gustave Roussy, Med Oncol, Villejuif, France
[2] Natl Taiwan Univ Hosp, Med Oncol, Taipei, Taiwan
[3] Peoples Liberat Army Canc Ctr, Med Oncol, Nanjing, Jiangsu, Peoples R China
[4] Harvard Med Sch, Massachusetts Gen Hosp, Boston, MA 02115 USA
[5] Natl Canc Ctr Hosp East, Med Oncol, Kashiwa, Chiba, Japan
[6] Seoul Natl Univ, Med Oncol, Coll Med, Seoul, South Korea
[7] F Hoffman La Roche Ltd, Roche Prod Dev, Shanghai, Peoples R China
[8] Genentech Inc, Prod Dev Oncol, San Francisco, CA 94080 USA
[9] Univ Calif Los Angeles, Geffen Sch Med, Los Angeles, CA USA
[10] Univ Med Ctr Mainz, Med Dept 1, Mainz, Germany
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
782TiP
引用
收藏
页码：267 / 267
页数：1
相关论文
共 50 条
  • [31] Reply to the Letter Regarding "Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study"
    Kudo, Masatoshi
    Tsuchiya, Kaoru
    Yamashita, Tatsuya
    Koga, Hironori
    Nakagawa, Yuki
    Ikeda, Masafumi
    LIVER CANCER, 2024, 13 (06) : 671 - 673
  • [32] Correspondence to editorial 2 on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: insights from the IMbrave150 trial"
    Yim, Sun Young
    Lee, Sung Hwan
    Kim, Ji Hoon
    Lee, Sunyoung S.
    Kaseb, Ahmed O.
    Lee, Ju-Seog
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [33] Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Galle, Peter R.
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Zhu, Andrew X.
    Kim, Tae-You
    Kudo, Masatoshi
    Breder, Valeriy Vladimirovich
    Merle, Philippe
    Kaseb, Ahmed Omar
    Li, Daneng
    Mulla, Sohail
    Verret, Wendy
    Xu, Derek-Zhen
    Hernandez, Sairy
    Liu, Juan
    Huang, Chen
    Lim, Ho Yeong
    Cheng, Ann-Lii
    Ducreux, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [34] Correspondence to letter to the editor on "Genomic biomarkers to predict response to atezolizumab plus bevacizumab immunotherapy in hepatocellular carcinoma: Insights from the IMbrave150 trial"
    Lee, Sung Hwan
    Yim, Sun Young
    Kim, Ji Hoon
    Lee, Sunyoung S.
    Kaseb, Ahmed
    Wei, Peng
    Lee, Ju-Seog
    CLINICAL AND MOLECULAR HEPATOLOGY, 2025, 31 (01)
  • [35] Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
    Chon, H.
    Song, Y. S.
    Yang, H.
    Kim, I.
    Hye-Young, K.
    Lee, W. S.
    Sang, Y. B.
    Kim, C.
    ANNALS OF ONCOLOGY, 2023, 34 : S611 - S611
  • [36] IMbrave152/SKYSCRAPER-14: a Phase III study of atezolizumab, bevacizumab and tiragolumab in advanced hepatocellular carcinoma
    Badhrinarayanan, Shreya
    Cotter, Christopher
    Zhu, Huaqi
    Lin, Ya-Chen
    Kudo, Masatoshi
    Li, Daneng
    FUTURE ONCOLOGY, 2024, 20 (28) : 2049 - 2057
  • [37] IMbrave150: updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC)
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Mertens, Joachim
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    SWISS MEDICAL WEEKLY, 2021, 151 : 25 - 26
  • [38] IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) 1 bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
    Cheng, A-L.
    Qin, S.
    Ikeda, M.
    Galle, P.
    Ducreux, M.
    Zhu, A.
    Kim, T-Y.
    Kudo, M.
    Breder, V.
    Merle, P.
    Kaseb, A.
    Li, D.
    Verret, W.
    Xu, Z.
    Hernandez, S.
    Liu, J.
    Huang, C.
    Mulla, S.
    Lim, H. Y.
    Finn, R.
    ANNALS OF ONCOLOGY, 2019, 30
  • [39] IMbrave150: Updated efficacy and safety by risk status in patients (pts) receiving atezolizumab (atezo) plus bevacizumab (bev) vs sorafenib (sor) as first-line treatment for unresectable hepatocellular carcinoma (HCC).
    Finn, Richard S.
    Qin, Shukui
    Ikeda, Masafumi
    Galle, Peter R.
    Ducreux, Michel
    Kim, Tae-You
    Kudo, Masatoshi
    Lim, Ho Yeong
    Breder, Valeriy
    Merle, Philippe
    Kaseb, Ahmed
    Li, Daneng
    Feng, Yin-Hsun
    Verret, Wendy
    Nicholas, Alan
    Li, Lindong
    Ma, Ning
    Zhu, Andrew X.
    Cheng, Ann-Lii
    CANCER RESEARCH, 2021, 81 (13)
  • [40] Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma
    Zhang, Xin
    Wang, Jingjing
    Shi, Juanjuan
    Jia, Xiaoli
    Dang, Shuangsuo
    Wang, Wenjun
    JAMA NETWORK OPEN, 2021, 4 (04)
12345